{'fraction_non_alphanumeric': 0.029743589743589743, 'fraction_numerical': 0.006153846153846154, 'mean_word_length': 5.777777777777778, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 1, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Management of recurrent transudative pleural effusions: can we REDUCE unnecessary interventions?

The management of recurrent, non-malignant pleural effusions has found itself in a quagmire. While significant advances in the field of malignant pleural diseases have occurred over the years, due to innovation and research efforts, this has not necessarily been the case in the field of non-malignant pleural diseases, except perhaps for pleural infections. Data suggests that despite having a “benign” problem, patients with recurrent, non-malignant pleural diseases may have one-year mortality rates in the range of 25–50% [1]. This, combined with nominally proven treatment options, leaves treating clinicians without confidence in what is truly the best therapeutic option for management. Indwelling pleural catheters and therapeutic thoracenteses seem to be equivalent therapeutic options for symptom palliation of recurrent symptomatic transudates https://bit.ly/3BifaaV